N Mattsson

Summary

Country: Sweden

Publications

  1. ncbi Biochemical markers in Alzheimer's disease clinical trials
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Biomark Med 4:91-8. 2010
  2. pmc CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
    N Mattsson
    Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA 94121, USA
    Transl Psychiatry 3:e293. 2013
  3. pmc Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults
    Niklas Mattsson
    Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA Electronic address
    Neurobiol Aging 35:614-22. 2014
  4. pmc Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
    Daniel Bremell
    Department of Infectious Medicine, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    BMC Neurol 13:2. 2013
  5. pmc CSF biomarker variability in the Alzheimer's Association quality control program
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Alzheimers Dement 9:251-61. 2013
  6. doi Amyloid-β metabolism in Niemann-Pick C disease models and patients
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Gothenburg, Sweden
    Metab Brain Dis 27:573-85. 2012
  7. doi Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:409-17. 2012
  8. doi Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:401-7. 2012
  9. doi Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 30:767-78. 2012
  10. pmc BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    PLoS ONE 7:e31084. 2012

Detail Information

Publications30

  1. ncbi Biochemical markers in Alzheimer's disease clinical trials
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Biomark Med 4:91-8. 2010
    ....
  2. pmc CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
    N Mattsson
    Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA 94121, USA
    Transl Psychiatry 3:e293. 2013
    ....
  3. pmc Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults
    Niklas Mattsson
    Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA Electronic address
    Neurobiol Aging 35:614-22. 2014
    ..Proteins interacting with CSF Aβ42 may be related to Aβ brain pathology, whereas proteins associated with atrophy even after adjusting for CSF Aβ42 may be related to Aβ-independent mechanisms. ..
  4. pmc Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
    Daniel Bremell
    Department of Infectious Medicine, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    BMC Neurol 13:2. 2013
    ..Like Borrelia burgdorferi, HIV also has neurotropic properties. Elevated serum CXCL13 concentrations have been reported in HIV patients, but data on CSF levels are limited...
  5. pmc CSF biomarker variability in the Alzheimer's Association quality control program
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Alzheimers Dement 9:251-61. 2013
    ..However, there are large variations in biomarker measurements among and within laboratories...
  6. doi Amyloid-β metabolism in Niemann-Pick C disease models and patients
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Gothenburg, Sweden
    Metab Brain Dis 27:573-85. 2012
    ..The preliminary findings from NPC cats suggest that treatment with cyclodextrin may have an impact on APP processing pathways. CSF Aβ, sAPP and tau biomarkers were dynamically altered over time in human NPC patients...
  7. doi Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:409-17. 2012
    ..We describe possible technical approaches, focusing on a selected reaction monitoring mass spectrometry assay as a candidate reference method for quantification of CSF amyloid β42...
  8. doi Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:401-7. 2012
    ..Global proficiency testing for CSF biomarkers is now fully established. It will continue to play an important part in the standardization of measurements that is a prerequisite for the broad-scale future implementation of CSF biomarkers...
  9. doi Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    J Alzheimers Dis 30:767-78. 2012
    ..Knowledge on these biomarkers and their trajectories may facilitate early diagnosis of AD and be useful in future clinical trials to track effects of disease modifying drugs...
  10. pmc BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    PLoS ONE 7:e31084. 2012
    ..The described CSF Aβ pattern may be used as a pharmacodynamic fingerprint to detect biochemical effects of BACE1-therapies in clinical trials, which might accelerate development of novel therapies...
  11. pmc Age and diagnostic performance of Alzheimer disease CSF biomarkers
    N Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at University of Gothenburg, Mo lndal, Sweden
    Neurology 78:468-76. 2012
    ..These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain pathology in cognitively unaffected elderly...
  12. pmc Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
    Alzheimers Res Ther 2:32. 2010
    ..Such biomarkers may be called 'theragnostic'. Here, we review the literature addressing the prospective value of these biomarkers...
  13. doi Converging pathways of chromogranin and amyloid metabolism in the brain
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Gothenburg and Mölndal, Sweden
    J Alzheimers Dis 20:1039-49. 2010
    ..Cell medium from BACE1-inhibited cells had decreased CgB levels. These results suggest that a large part of AbetaPP in the human central nervous system is processed in the regulated secretory pathway of neurons...
  14. ncbi Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis
    Niklas Mattsson
    Department of Neurochemistry and Psychiatry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Neurochem 103:1932-9. 2007
    ..Further studies will investigate the involvement of these peptides in MS pathogenesis...
  15. doi Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis
    N Mattsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Mult Scler 15:448-54. 2009
    ..Cell and animal experiments have shown that beta-site APP-cleaving enzyme 1 (BACE1) may be involved in myelination...
  16. doi Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Eur Neurol 62:200-3. 2009
    ..A number of tentative solutions to the problem, apart from better tests, are discussed...
  17. doi CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    JAMA 302:385-93. 2009
    ....
  18. doi Converging molecular pathways in human neural development and degeneration
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Göteborg Mölndal, Sweden
    Neurosci Res 66:330-2. 2010
    ..Tau phosphorylation in Alzheimer's disease may be a physiological response to Alzheimer-associated synaptotoxicity...
  19. pmc The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Alzheimers Dement 7:386-395.e6. 2011
    ..In this article, we present the results from the first two rounds of the program...
  20. doi Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, S 431 80 Molndal, Sweden
    Neuromolecular Med 13:151-9. 2011
    ..Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology...
  21. doi Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Sahlgren s University Hospital Mölndal, S 431 80 Molndal, Sweden
    Mol Med Report 1:757-61. 2008
    ..Taken together, these data suggest that differentially-expressed peptides are general markers of axonal degeneration. Further studies are needed to verify their prognostic value in FTD...
  22. doi Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall
    Niklas Mattsson
    Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Institute of Neuroscience and Physiology, Göteborg and Mölndal, Sweden
    Clin Chem Lab Med 48:603-7. 2010
    ..Here, we discuss the causes of these variations, and present a global quality control program to overcome them...
  23. pmc Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study
    N Mattsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    Neurology 76:366-72. 2011
    ..Our aim was to assess the effect of altered lipid constituents in neuronal membranes on amyloidogenic APP processing in humans...
  24. pmc Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    BMC Neurol 10:51. 2010
    ..We have previously found altered cerebral amyloid metabolism in other neuroinflammatory conditions. To further elucidate this, we investigated amyloid metabolism in patients with Lyme neuroborreliosis (LNB)...
  25. doi CSF biomarkers in neurodegenerative diseases
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Clin Chem Lab Med 49:345-52. 2011
    ..This article reviews the definitions, usage and current limitations of CSF biomarkers in this field...
  26. doi Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis
    N Mattsson
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Intern Med 265:459-64. 2009
    ....
  27. ncbi Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Alzheimers Dis 12:255-60. 2007
    ..Thus, even minor biochemical changes induced by treatment against AD should be detectable using these biomarkers, which bodes well for their usefulness as surrogate markers for drug efficacy in clinical trials...
  28. doi Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures
    P Shahim
    Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska University Hospital Molndal, Molndal, Sweden
    Eur J Neurol 21:486-91. 2014
    ....
  29. doi CSF biomarkers: pinpointing Alzheimer pathogenesis
    Niklas Mattsson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
    Ann N Y Acad Sci 1180:28-35. 2009
    ..Here, we review available CSF biomarkers for these pathological processes. We also consider their usability in clinical practice and in clinical trials...
  30. ncbi Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, Sahlgren s University Hospital, S 431 80 Molndal, Sweden
    Neurosci Lett 414:233-6. 2007
    ..360, p=0.012). These results suggest that siblings of MS patients have an increased oxidative stress response to environmental and/or genetic factors that may be involved in MS pathogenesis...